GlassScriptPhysician profile
Thaila Ramanujam
NPI 1801999206
$225,179.66
in general payments reported to CMS, 2019-2025
28 companies · $25K in 2025
The $25K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81K · 2020: $19K · 2021: $16K · 2022: $24K · 2023: $29K · 2024: $30K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Consulting Fee: $25K · Travel and Lodging: $9,617 · Food and Beverage: $8,902 · Honoraria: $5,200 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,773.00 |
| Consulting Fee | $24,550.75 |
| Travel and Lodging | $9,617.14 |
| Food and Beverage | $8,901.61 |
| Honoraria | $5,200.00 |
| Education | $153.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $69,479.94 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Janssen Biotech, INC. | $47,611.91 | 2019-2025 | Simponi Aria, Tremfya, Stelara |
| Horizon Therapeutics Plc | $32,352.50 | 2019-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $22,236.02 | 2019-2025 | Cosentyx |
| Abbvie INC. | $10,152.26 | 2019-2025 | |
| Genzyme Corporation | $9,577.99 | 2019-2025 | |
| Ucb, INC. | $8,239.36 | 2019-2025 | Bimzelx, Cimzia |
| Gilead Sciences, INC. | $5,493.23 | 2019-2020 | |
| Lilly USA, LLC | $5,261.47 | 2019-2024 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $3,860.82 | 2019-2025 | Orencia, Sotyktu |
| Amgen INC. | $3,267.13 | 2019-2025 | Krystexxa, Enbrel, Evenity |
| Sobi, INC | $2,623.32 | 2025 | |
| Janssen Global Services, LLC | $2,000.00 | 2021 | |
| Glaxosmithkline, LLC. | $866.11 | 2019-2025 | Benlysta |
| Pfizer INC. | $524.70 | 2019-2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $336.05 | 2019 | |
| Celgene Corporation | $274.82 | 2019 | |
| Genentech USA, INC. | $236.09 | 2019-2024 | Ocrevus, Xolair |
| Astrazeneca Pharmaceuticals LP | $197.05 | 2021-2024 | Saphnelo |
| Aurinia Pharma U.S., INC. | $135.06 | 2021-2024 | Lupkynis |
| Eisai INC. | $124.92 | 2024 | |
| Alexion Pharmaceuticals, INC. | $112.18 | 2021-2023 | Strensiq |
| Mallinckrodt Hospital Products INC. | $79.06 | 2020-2024 | Acthar |
| Merck Sharp & Dohme LLC | $65.41 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.36 | 2020-2023 | Ofev |
| Lundbeck LLC | $23.16 | 2024 | Vyepti |
| Hikma Pharmaceuticals USA | $13.74 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thaila Ramanujam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.